Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

@article{Leblond2013ResultsOA,
  title={Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr{\"o}m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.},
  author={V{\'e}ronique Leblond and Steve P Johnson and Sylvie Chevret and Adrian Copplestone and Simon Rule and Olivier Tournilhac and John F Seymour and Russell D Patmore and David G. Wright and Pierre Morel and M S Dilhuydy and Sara Willoughby and Caroline Dartigeas and Marion Malphettes and Bruno Royer and Maeve Ewings and Guy Pratt and Julie Lejeune and Florence Nguyen-Khac and Sylvain Choquet and Roger G. Owen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 3},
  pages={301-7}
}
PURPOSE Treatment options for patients with Waldenström macroglobulinemia (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibodies. No large randomized studies have yet been reported comparing any of these approaches. PATIENTS AND METHODS The randomized WM1 study (Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia) was undertaken in 101 centers in five countries enrolling 414 eligible patients (339… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS